Functional malignant cell heterogeneity in pancreatic neuroendocrine tumors revealed by targeting of PDGF-DD

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 7, 2016, Pages E864-E873

  Cortez, Eliane ^a   Gladh, Hanna ^b   Braun, Sebastian ^a   Bocci, Matteo ^a   Cordero, Eugenia ^a   K Björkström, Niklas ^b   Miyazaki, Hideki ^a   Michael, Iacovos P ^c   Eriksson, Ulf ^b   Folestad, Erika ^b   Pietras, Kristian ^a  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c EPFL   (Switzerland)

Author keywords

Neuroendocrine tumor; Platelet derived growth factor DD; Tumor heterogeneity

Indexed keywords

PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR DD; UNCLASSIFIED DRUG; LYMPHOKINE; PDGFD PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL FUNCTION; CELL HETEROGENEITY; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STROMA; TUMOR GROWTH; VALIDATION STUDY; ANIMAL; GENETICS; NEOVASCULARIZATION (PATHOLOGY); NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PATHOLOGY; VASCULARIZATION;

ANIMALS; CELL PROLIFERATION; LYMPHOKINES; MICE; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PLATELET-DERIVED GROWTH FACTOR;

EID: 84958818888     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1509384113     Document Type: Article

References (56)

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
2. Cortez E, Roswall P, Pietras K (2014) Functional subsets of mesenchymal cell types in the tumor microenvironment. Semin Cancer Biol 25:3-9.
3. Gerlinger M, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883-892.
4. Heldin C-H, Westermark B (1999) Mechanism of action and in vivo role of plateletderived growth factor. Physiol Rev 79(4):1283-1316.
5. Pietras K, Sjöblom T, Rubin K, Heldin CH, Ostman A (2003) PDGF receptors as cancer drug targets. Cancer Cell 3(5):439-443.
6. Demetri GD, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472-480.
7. Druker BJ, et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344(14):1038-1042.
8. Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22(10):1276-1312.
9. Bergsten E, et al. (2001) PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol 3(5):512-516.
10. LaRochelle WJ, et al. (2001) PDGF-D, a new protease-activated growth factor. Nat Cell Biol 3(5):517-521.
11. Hanahan D (1985) Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315(6015):115-122.
12. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111(9):1287-1295.
13. Anderberg C, et al. (2013) Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. J Exp Med 210(3):563-579.
14. Wu Q, et al. (2013) Emerging roles of PDGF-D in EMT progression during tumorigenesis. Cancer Treat Rev 39(6):640-646.
15. Lindblom P, et al. (2003) Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 17(15):1835-1840.
16. Xian X, et al. (2006) Pericytes limit tumor cell metastasis. J Clin Invest 116(3): 642-651.
17. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G (2005) PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7(9):870-879.
18. Franco M, Pàez-Ribes M, Cortez E, Casanovas O, Pietras K (2011) Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy. Horm Metab Res 43(12):884-889.
19. Uutela M, et al. (2004) PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. Blood 104(10):3198-3204.
20. Nozawa H, Chiu C, Hanahan D (2006) Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 103(33):12493-12498.
21. Duerr EM, et al. (2008) Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer 15(1):243-256.
22. Tornehave D, Kristensen P, Rømer J, Knudsen LB, Heller RS (2008) Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem 56(9): 841-851.
23. Gong S, et al. (2003) A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425(6961):917-925.
24. Efrat S, et al. (1988) Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene. Proc Natl Acad Sci USA 85(23):9037-9041.
25. O'Connor DT, Deftos LJ (1986) Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 314(18):1145-1151.
26. Xu L, Tong R, Cochran DM, Jain RK (2005) Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res 65(13):5711-5719.
27. Kong D, et al. (2009) miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 27(8):1712-1721.
28. Kong D, et al. (2008) Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells 26(6): 1425-1435.
29. Liu J, et al. (2011) PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin Cancer Res 17(11):3638-3648.
30. Li H, Fredriksson L, Li X, Eriksson U (2003) PDGF-D is a potent transforming and angiogenic growth factor. Oncogene 22(10):1501-1510.
31. Ustach CV, et al. (2004) A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer Res 64(5):1722-1729.
32. Wang Z, et al. (2010) Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta 1806(1):122-130.
33. Abramsson A, Lindblom P, Betsholtz C (2003) Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 112(8):1142-1151.
34. Franco M, Roswall P, Cortez E, Hanahan D, Pietras K (2011) Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood 118(10):2906-2917.
35. Butler JM, Kobayashi H, Rafii S (2010) Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 10(2): 138-146.
36. Cao Z, et al. (2014) Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance. Cancer Cell 25(3):350-365.
37. Seton-Rogers S (2014) Microenvironment: Endothelial cells create a niche. Nat Rev Cancer 14(5):298.
38. Uutela M, et al. (2001) Chromosomal location, exon structure, and vascular expression patterns of the human PDGFC and PDGFD genes. Circulation 103(18):2242-2247.
39. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA (2002) Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: Evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62(13):3729-3735.
40. Pietras K, Ostman A (2010) Hallmarks of cancer: Interactions with the tumor stroma. Exp Cell Res 316(8):1324-1331.
41. Levéen P, et al. (1994) Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 8(16):1875-1887.
42. Soriano P (1994) Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev 8(16):1888-1896.
43. Ehnman M, Li H, Fredriksson L, Pietras K, Eriksson U (2009) The uPA/uPAR system regulates the bioavailability of PDGF-DD: Implications for tumour growth. Oncogene 28(4):534-544.
44. Chen H, et al. (2011) PDGF signalling controls age-dependent proliferation in pancreatic β-cells. Nature 478(7369):349-355.
45. Gerlinger M, et al. (2014) Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 46(3):225-233.
46. Zhang J, et al. (2014) Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346(6206):256-259.
47. Inda MM, et al. (2010) Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 24(16):1731-1745.
48. Marusyk A, et al. (2014) Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 514(7520):54-58.
49. Archetti M, Ferraro DA, Christofori G (2015) Heterogeneity for IGF-II production maintained by public goods dynamics in neuroendocrine pancreatic cancer. Proc Natl Acad Sci USA 112(6):1833-1838.
50. Gupta PB, et al. (2011) Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146(4):633-644.
51. Fjällskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET (2003) Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 9(4):1469-1473.
52. Fjällskog ML, Hessman O, Eriksson B, Janson ET (2007) Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol 46(6):741-746.
53. Banck MS, et al. (2013) The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest 123(6):2502-2508.
54. Raymond E, et al. (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501-513.
55. Pietras K, Hanahan D (2005) A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23(5):939-952.
56. Cunha SI, et al. (2010) Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med 207(1):85-100.